



IQWiG Reports – Commission No. A19-69

**Ivacaftor  
(cystic fibrosis, 12 to < 24  
months, with gating  
mutations) –**

**Benefit assessment according to §35a  
Social Code Book V<sup>1</sup>**

**Extract**

---

<sup>1</sup> Translation of Sections 2.1 to 2.6 of the dossier assessment *Ivacaftor (zystische Fibrose, 12 bis < 24 Monate, mit Gating-Mutationen) – Nutzenbewertung gemäß § 35a SGB V* (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

# Publishing details

**Publisher:**

Institute for Quality and Efficiency in Health Care

**Topic:**

Ivacaftor (cystic fibrosis, 12 to < 24 months, with gating mutations) – Benefit assessment according to §35a Social Code Book V

**Commissioning agency:**

Federal Joint Committee

**Commission awarded on:**

28 August 2019

**Internal Commission No.:**

A19-69

**Address of publisher:**

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen  
Im Mediapark 8  
50670 Köln  
Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

E-mail: [berichte@iqwig.de](mailto:berichte@iqwig.de)

Internet: [www.iqwig.de](http://www.iqwig.de)

**Medical and scientific advice:**

No advisor on medical and scientific questions was available for the present dossier assessment.

**IQWiG employees involved in the dossier assessment:**

- Kirsten Janke
- Christiane Balg
- Katharina Biester
- Michaela Florina Kerekes
- Marco Knelangen
- Ulrike Mikulić
- Min Ripoll
- Cornelia Rüdiger
- Anke Schulz

**Keywords:** Ivacaftor, Cystic Fibrosis, Infant, Benefit Assessment, NCT02725567, NCT00909532, NCT00909727

# Table of contents

	<b>Page</b>
<b>List of tables</b> .....	<b>iv</b>
<b>List of abbreviations</b> .....	<b>v</b>
<b>2 Benefit assessment</b> .....	<b>1</b>
<b>2.1 Executive summary of the benefit assessment</b> .....	<b>1</b>
<b>2.2 Research question</b> .....	<b>5</b>
<b>2.3 Information retrieval and study pool</b> .....	<b>5</b>
<b>2.4 Results on added benefit</b> .....	<b>9</b>
<b>2.5 Probability and extent of added benefit</b> .....	<b>9</b>
<b>2.6 List of included studies</b> .....	<b>9</b>
<b>References for English extract</b> .....	<b>9</b>

**List of tables<sup>2</sup>**

	<b>Page</b>
Table 2: Research questions of the benefit assessment of ivacaftor .....	1
Table 3: Ivacaftor – probability and extent of added benefit .....	4
Table 4: Research questions of the benefit assessment of ivacaftor .....	5
Table 5: Ivacaftor – probability and extent of added benefit .....	9

---

<sup>2</sup> Table numbers start with “2” as numbering follows that of the full dossier assessment.

**List of abbreviations**

<b>Abbreviation</b>	<b>Meaning</b>
ACT	appropriate comparator therapy
BSC	best supportive care
CF	cystic fibrosis
CFTR	cystic fibrosis transmembrane conductance regulator
FEV1	forced expiratory volume in 1 second
G-BA	Gemeinsamer Bundesausschuss (Federal Joint Committee)
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care)
LCI	lung clearance index
RCT	randomized controlled trial
SGB	Sozialgesetzbuch (Social Code Book)

## 2 Benefit assessment

### 2.1 Executive summary of the benefit assessment

#### Background

In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug ivacaftor. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 28 August 2019.

#### Research question

The aim of the present report is the assessment of the added benefit of ivacaftor in comparison with the appropriate comparator therapy (ACT) best supportive care (BSC) in patients with cystic fibrosis (CF) from 12 months to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

Table 2: Research questions of the benefit assessment of ivacaftor

Therapeutic indication	ACT <sup>a</sup>
Patients with cystic fibrosis from 12 to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N or S549R	BSC <sup>b</sup>
a: Presentation of the ACT specified by the G-BA. b: BSC refers to the therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve the quality of life. ACT: appropriate comparator therapy; BSC: best supportive care; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee	

The company named BSC as ACT and thus followed the G-BA’s specification.

The assessment was made by means of patient-relevant outcomes on the basis of the data presented by the company in the dossier. Randomized controlled trials (RCTs) with a minimum duration of 24 weeks were used for the derivation of the added benefit.

#### Results

The company did not identify any relevant RCTs for the comparison of ivacaftor versus the ACT BSC in the present therapeutic indication. For this reason, it presented results from the single-arm study VX15-770-124, which was to include children with CF who are from 12 to < 24 months of age and have one of the following CFTR gating mutations in at least one allele: G551D, G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N or S549R. The study had 2 parts (Part A and B), with Part B lasting 24 weeks. The company considered Part B for the

benefit assessment. The company did not search for data on the ACT. Since the VX15-770-124 study was only a single-arm study, the company additionally referred to 3 RCTs in older patients (aged 6 years and older). From the company's point of view, it would be possible to transfer these data to children from 12 to < 24 months of age and use them for the derivation of an added benefit. It justified this with a comparability of mechanism of action of the intervention, of manifestation of the disease and of efficacy and safety of ivacaftor, which it considered sufficient for children from 12 to < 24 months of age and patients aged 6 years and older. According to the company, the evidence on patients aged 6 years and older can therefore be used for the derivation of an added benefit in children from 12 to < 24 months of age. The studies VX12-770-111, VX08-770-102 and VX08-770-103 on patients aged 6 years and older are subject of the dossier assessments on commissions A19-65 and A19-66.

### ***Transfer of the added benefit not possible***

The company's approach to transfer study results from older patients to the population relevant for the benefit assessment is comprehensible due to the lack of directly comparative data in children from 12 to < 24 months of age. The concrete approach adopted by the company is unsuitable for this, however. An added benefit of ivacaftor versus the ACT in children from 12 to < 24 months of age cannot be derived from the data presented by the company for the following reasons:

#### *Studies VX12-770-111, VX08-770-102 and VX08-770-103*

The VX12-770-111 study is a randomized crossover study with a treatment duration of 8 weeks. It included patients aged 6 years and older with the following gating mutations: G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N, S549R or G970R. The treatment duration of 8 weeks is too short for a benefit assessment in the therapeutic indication of CF.

The studies VX08-770-102 and VX08-770-103 are RCTs with a treatment duration of 48 weeks. These studies included patients aged 12 years and older (VX08-770-102) and from 6 to 11 years (VX08-770-103) with the gating mutation G551D. The transferability of the data from these 2 studies to children from 12 to < 24 months of age is inadequate for the following reasons:

- Different effects of ivacaftor versus BSC depending on disease stage
  - CF is a progressive disease. Hence, the greater the age difference between the population to be assessed and the population from which the transfer is to be made, the more questionable the transferability of results appears. The data presented on the 2 studies VX08-770-102 and VX08-770-103 show differences in demographic and clinical characteristics of the populations included. In addition, there are different effects of ivacaftor versus the ACT BSC in patient-relevant outcomes. Based on the data presented, it is assumed that, due to the progressive course of CF and the large age difference between the study populations, the children in the VX08-770-103 study were in a less advanced stage of disease than the patients in the VX08-770-102 study. For this reason, it is not meaningful to transfer results of the study population from the

VX08-770-102 study to even younger children, i.e. children from 12 to < 24 months of age. This is a reason against the transferability of the effects from the VX08-770-102 study (patients aged 12 years and older) to children from 12 to < 24 months of age.

- Lack of data for the assessment of the comparability of the outcomes of the VX15-770-124 study with study VX08-770-103

Due to a lack of data, it was not possible to assess the comparability for the following important parameters:

- The studies used by the company used different operationalizations for pulmonary exacerbation, a key patient-relevant outcome in the therapeutic indication of CF. For this outcome, there is no processing of the data based on comparable operationalizations for the studies VX15-770-124 and VX08-770-103. A transfer of the results from the VX08-770-103 study to children from 12 to < 24 months of age is therefore inadequate.
- No data for a comparison are available on lung function parameters for the different age groups. The forced expiratory volume in 1 second (FEV1) was not recorded at all in the study on children from 12 to < 24 months of age, and the lung clearance index (LCI) was recorded in both studies in a proportion of children that was too small.

Regardless of whether transferability of the results from the VX08-770-103 study to children from 12 to < 24 months of age is possible, based on the outcomes considered for the assessment on Commission A19-65, there were neither effects in favour nor effects to the disadvantage of ivacaftor + BSC versus BSC in the VX08-770-103 study.

- Missing data on the appropriate comparator therapy BSC
  - The company did not present any data from studies with the ACT BSC for children from 12 to < 24 months of age, so that the treatment effects of ivacaftor versus BSC cannot be estimated.

### **Probability and extent of added benefit, patient groups with therapeutically important added benefit<sup>3</sup>**

Based on the results presented, probability and extent of the added benefit of the drug ivacaftor in comparison with the ACT are assessed as follows:

Table 3 shows a summary of probability and extent of the added benefit of ivacaftor.

---

<sup>3</sup> On the basis of the scientific data analysed, IQWiG draws conclusions on the (added) benefit or harm of an intervention for each patient-relevant outcome. Depending on the number of studies analysed, the certainty of their results, and the direction and statistical significance of treatment effects, conclusions on the probability of (added) benefit or harm are graded into 4 categories: (1) “proof”, (2) “indication”, (3) “hint”, or (4) none of the first 3 categories applies (i.e., no data available or conclusions 1 to 3 cannot be drawn from the available data). The extent of added benefit or harm is graded into 3 categories: (1) major, (2) considerable, (3) minor (in addition, 3 further categories may apply: non-quantifiable extent of added benefit, added benefit not proven, or less benefit). For further details see [1,2].

Table 3: Ivacaftor – probability and extent of added benefit

Therapeutic indication	ACT <sup>a</sup>	Probability and extent of added benefit
Patients with cystic fibrosis from 12 to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R	BSC <sup>b</sup>	Added benefit not proven
<p>a: Presentation of the ACT specified by the G-BA.  b: BSC refers to the therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve the quality of life.  ACT: appropriate comparator therapy; BSC: best supportive care; CFTR: cystic fibrosis transmembrane conductance regulator;  G-BA: Federal Joint Committee</p>		

The G-BA decides on the added benefit.

## 2.2 Research question

The aim of the present report is the assessment of the added benefit of ivacaftor in comparison with the ACT BSC in patients with CF from 12 months to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

Table 4: Research questions of the benefit assessment of ivacaftor

Therapeutic indication	ACT <sup>a</sup>
Patients with cystic fibrosis from 12 to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N or S549R	BSC <sup>b</sup>
<p>a: Presentation of the ACT specified by the G-BA.  b: BSC refers to the therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve the quality of life.  ACT: appropriate comparator therapy; BSC: best supportive care; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee</p>	

The company named BSC as ACT and thus followed the G-BA's specification.

The assessment was made by means of patient-relevant outcomes on the basis of the data presented by the company in the dossier. RCTs with a minimum duration of 24 weeks were used for the derivation of the added benefit. This deviates from the company's inclusion criteria, which specified a minimum duration of 8 weeks.

## 2.3 Information retrieval and study pool

The study pool of the assessment was compiled on the basis of the following information:

Sources of the company in the dossier:

- study lists on ivacaftor (status: 4 June 2019)
- bibliographical literature search on ivacaftor (status: 4 June 2019)
- search in trial registries for studies on ivacaftor (status: 4 June 2019)

To check the completeness of the study pool:

- search in trial registries for studies on ivacaftor (last search on 5 September 2019)

Concurring with the company, the check of the completeness of the study pool produced no relevant RCTs for a comparison of ivacaftor versus the ACT BSC in the present therapeutic indication.

The company presented results from the single-arm study VX15-770-124 [3-7] in children from 12 to < 24 months of age for the derivation of the added benefit. The company did not search

for data on the ACT. Since the VX15-770-124 study was only a single-arm study, the company additionally referred to 3 RCTs in older patients (aged 6 years and older). From the company's point of view, it would be possible to transfer these data to children from 12 to < 24 months of age and use them for the derivation of an added benefit. It justified this with a comparability of mechanism of action of the intervention, of manifestation of the disease and of efficacy and safety of ivacaftor, which it considered sufficient for children from 12 to < 24 months of age and patients aged 6 years and older. The company did not provide any processing of the data it considered relevant for the transfer of the results.

The company's approach to transfer study results from older patients to the population relevant for the present benefit assessment is comprehensible due to the lack of directly comparative data in children from 12 to < 24 months of age. The concrete approach adopted by the company is unsuitable for this, however. An added benefit of ivacaftor versus the ACT in children from 12 to < 24 months of age cannot be derived from the data presented by the company. This is justified below.

#### **Single-arm study with ivacaftor (VX15-770-124)**

The VX15-770-124 study is a single-arm, open-label study with ivacaftor, which was to include children with CF from 0 to < 24 months of age who have one of the following CFTR gating mutations in at least one allele: G551D, G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N or S549R. The study was conducted in 2 parts and time periods (Part A and Part B). Depending on their age, the children were divided into 4 cohorts in Part A and 3 cohorts in Part B. Ivacaftor granules were administered with a weight-adjusted dosage both in Part A and in Part B of the study. Both parts of the study differed in the outcomes investigated and in treatment duration. Whereas treatment in Part A was 4 days, treatment in Part B was 24 weeks. Due to the treatment duration, the company did not consider the Part A study phase for the benefit assessment, but only Part B. Children from 12 to < 24 months of age were included in cohort 5 of this part of the study. Treatment with ivacaftor in the study was in addition to concomitant treatment for the therapy of CF. Cohort 5 of the study included 19 children. With respect to the gating mutations, children included in the VX15-770-124 study only had the mutations G551D, S549R and G178R (G551D: 16 children, S549R: 2 children, G178R: 1 child). Further information on the characteristics of the study, the intervention, the included patients and the concomitant treatment can be found in Table 9 to Table 12 in Appendix A of the full dossier assessment.

#### **Transfer of the added benefit not possible**

In its argumentation on an added benefit of ivacaftor in the present therapeutic indication, the company referred to results from the studies VX12-770-111, VX08-770-102 and VX08-770-103 with patients aged 6 years and older. The company considered it possible to transfer the results from these 3 studies to the target population of children from 12 to < 24 months of age. The company aimed to transfer the added benefit from older patients with the same mutations to children from 12 to < 24 months of age.

***Studies VX12-770-111, VX08-770-102 and VX08-770-103***

The company presented the studies, the results of which it transferred to the present therapeutic indication for the derivation of the added benefit, in the dossier also in Module 4 B (VX12-770-111) and in Module 4 A (VX08-770-102 and VX08-770-103).

The VX12770-111 study is a randomized crossover study with a treatment duration of 8 weeks. The study included patients aged 6 years and older with the following gating mutations: G551S, G1244E, G1349D, G178R, S1251N, S1255P, S549N, S549R or G970R. With a treatment duration of 8 weeks, however, it is too short to be included in the benefit assessment in the therapeutic indication of CF. Detailed information on this study can be found in dossier assessment on Commission A19-66 [8].

The studies VX08-770-102 and VX08-770-103 are RCTs with a treatment duration of 48 weeks. These studies included patients aged 12 years and older (VX08-770-102) and from 6 to 11 years (VX08-770-103) with the gating mutation G551D. Both of these studies are subject of the dossier assessment on Commission A19-65 [9]. Information on the characteristics of the studies, the interventions and the included patients regarding these studies can be found in Table 13 to Table 15 in Appendix B of the full dossier assessment.

The company justified the transferability of the results of older patients to the target population with a comparability of mechanism of action of the intervention, of manifestation of the disease and of efficacy and safety, which it considered sufficient. The company's approach for a transfer is inadequate. The following aspects in particular are decisive for this:

- Different effects of ivacaftor versus BSC depending on disease stage
  - CF is a progressive disease. Hence, the greater the age difference between the population to be assessed and the population from which the transfer is to be made, the more questionable the transferability of results appears. The consideration of the results of the VX08-770-102 study (patients aged 12 years and older) and of the VX08-770-103 study (children aged 6 to 11 years) show differences in the demographic and clinical characteristics of the included populations, which resulted mainly from the different inclusion and exclusion criteria of the studies. Due to the different populations and following the company, no meta-analytic summary of the results from the 2 studies mentioned above was conducted in the benefit assessment on Commission A19-65. In addition, there are different effects of ivacaftor versus the ACT BSC in patient-relevant outcomes (see dossier assessment on Commission A19-65 [9]). Overall, based on the data presented, it is assumed that, due to the progressive course of CF and the large age difference between the study populations, the children in the VX08-770-103 study were in a less advanced stage of disease than the patients in the VX08-770-102 study. For this reason, it is not meaningful to transfer results of the study population from the VX08-770-102 study to even younger children, i.e. children from 12 to < 24 months of age. This is a reason against the

transferability of the effects from the VX08-770-102 study (patients aged 12 years and older) to children from 12 to < 24 months of age.

- Lack of data for the assessment of the comparability of the outcomes of the VX15-770-124 study with study VX08-770-103

The results from the VX15-770-124 study in children from 12 to < 24 months of age and of the VX08-770-103 study in children aged 6 to 11 years are presented in Table 17 to Table 19 in Appendix C of the full dossier assessment.

Due to a lack of data, it was not possible to assess the comparability for the following important parameters:

- Compared with the VX11-770-103 study in children between 6 and 11 years of age, the VX15-770-124 study in children from 12 to < 24 months of age used different operationalizations for pulmonary exacerbation, a key patient-relevant outcome in the therapeutic indication of CF. These differ both regarding the symptoms included in the operationalizations and regarding the persistence of the symptoms. An overview of the operationalizations used in the studies can be found in Table 16 in Appendix C of the full dossier assessment. The company did not provide any processing of the data according to comparable operationalizations for the 2 studies for this outcome. The VX15-770-124 study used 2 different operationalizations, which produced clearly different results already within this study. Besides, the results of this study VX15-770-124 differed clearly from the results of the VX08-770-103 study for both operationalizations considered. The cause of the differences in the results between the studies regarding this outcome can therefore not be assessed. A transfer of the results from the VX08-770-103 study to children from 12 to < 24 months of age is therefore inadequate.
- No data for a comparison are available on lung function parameters for the different age groups. The FEV1 was not recorded at all in the VX15-770-124 study, and the LCI was recorded in both studies in a proportion of children that was too small (VX15-770-124: 1 of 19 children; VX08-770-103: 2 of 38 children in the relevant subpopulation).
- Missing data on the appropriate comparator therapy BSC
  - The company did not present any data from studies with the ACT BSC for children from 12 to < 24 months of age, so that the treatment effects of ivacaftor versus BSC cannot be estimated. It did not address the question in the dossier why it had not conducted a literature search on the ACT.

In summary, the company's implementation of the transfer of the presented study results on patients aged 6 years and older to the target population for the derivation of the added benefit is unsuitable as the transferability of the evidence from children from 6 to 11 years of age cannot be adequately assessed due to insufficient data availability. Different effects are already shown for patients aged 12 years and older in comparison with children from 6 to 11 years of age, so

that a transfer of the results to even younger children is considered unsuitable. Regardless of whether transferability of the results is possible, based on the outcomes considered for the benefit assessment, the VX08-770-103 study provided neither effects in favour nor effects to the disadvantage of ivacaftor + BSC versus BSC (see dossier assessment on Commission A19-65).

## 2.4 Results on added benefit

The company did not present any suitable data for the assessment of the added benefit of ivacaftor versus the ACT BSC. This resulted in no hint of an added benefit of ivacaftor in comparison with the ACT; an added benefit is therefore not proven.

## 2.5 Probability and extent of added benefit

The result of the assessment of the added benefit of ivacaftor in comparison with the ACT is summarized in Table 5.

Table 5: Ivacaftor – probability and extent of added benefit

Therapeutic indication	ACT <sup>a</sup>	Probability and extent of added benefit
Patients with cystic fibrosis from 12 to < 24 months of age and weighing between 7 kg and less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R	BSC <sup>b</sup>	Added benefit not proven
a: Presentation of the ACT specified by the G-BA. b: BSC refers to the therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve the quality of life. ACT: appropriate comparator therapy; BSC: best supportive care; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee		

The assessment described above deviates from that of the company, which derived a considerable added benefit without addressing its probability.

The G-BA decides on the added benefit.

## 2.6 List of included studies

Not applicable as the company did not present any relevant data for the benefit assessment.

## References for English extract

Please see full dossier assessment for full reference list.

The reference list contains citations provided by the company in which bibliographical information may be missing.

1. Institute for Quality and Efficiency in Health Care. General methods: version 5.0 [online]. 10.07.2017 [Accessed: 04.06.2018]. URL: [https://www.iqwig.de/download/General-Methods\\_Version-5-0.pdf](https://www.iqwig.de/download/General-Methods_Version-5-0.pdf).
2. Skipka G, Wieseler B, Kaiser T, Thomas S, Bender R, Windeler J et al. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. *Biom J* 2015; 58(1): 43-58.
3. A study to evaluate the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in subjects with cystic fibrosis who are less than 24 months of age and have a CFTR gating mutation [online]. In: *ClinicalTrials.gov*. [Accessed: 04.06.2019]. URL: <https://clinicaltrials.gov/ct2/show/NCT02725567>.
4. A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs) [online]. In: *International Clinical Trials Registry Plattform*. [Accessed: 07.06.2019]. URL: <http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001997-16-GB>.
5. A phase 3, 2-part, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in subjects with cystic fibrosis who are less than 24 months of age at treatment initiation and have a CFTR gating mutation [online]. In: *EU Clinical Trials Register*. [Accessed: 07.06.2019]. URL: <https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001997-16>.
6. Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. *Lancet Respir Med* 2018; 6(7): 545-553.
7. Vertex Pharmaceuticals. A phase 3, 2-part, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in subjects with cystic fibrosis WHO are less than 24 months of age at treatment initiation and have a CFTR Gating Mutation: analysis of subjects 12 to <24 months of age (cohorts 1 and 5); study VX15-770-124; interim analysis report [unpublished]. 2018.
8. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ivacaftor (zystische Fibrose, ab 6 Jahre, mit non-G551D-Gating-Mutation): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A19-66. Köln: IQWiG; 2019.
9. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ivacaftor (zystische Fibrose, ab 6 Jahre, mit G551D-Mutation): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A19-65. Köln: IQWiG; 2019.

*The full report (German version) is published under <https://www.iqwig.de/en/projects-results/projects/drug-assessment/a19-69-ivacaftor-cystic-fibrosis-from-12-to-24-months-with-gating-mutations-benefit-assessment-according-to-35a-social-code-book-v.12572.html>.*